LAS190792

a muscarinic antagonist and beta2-adrenoceptor agonist

Also Known As:

(trans)-4-((2-(((2-chloro-4-((((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)carbamoyl)oxy)ethyl)(methyl)amino)cyclohexyl 2-hydroxy-2,2-di(thiophen-2-yl)acetate; AZD8999

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        LAS190792: 2
- Sulfur Compounds: 278
  - Thiophenes: 257
    - LAS190792: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - LAS190792: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - LAS190792: 2

Experts

1.	Aparici, Mònica: 2 articles (01/2019 - 10/2017)
2.	Cortijo, Julio: 2 articles (01/2019 - 10/2017)
3.	Miralpeix, Montserrat: 2 articles (01/2019 - 10/2017)
4.	Calbet, Marta: 1 article (01/2019)
5.	Contreras, Sonia: 1 article (01/2019)
6.	Milara, Javier: 1 article (01/2019)
7.	Morcillo, Esteban: 1 article (01/2019)
8.	de Diego, Alfredo: 1 article (01/2019)
9.	Carcasona, Carla: 1 article (10/2017)
10.	Doe, Chris: 1 article (10/2017)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2019 - "This study investigates the anti-inflammatory effects of AZD8999 in monotherapy and combined with fluticasone propionate in neutrophils from healthy and chronic obstructive pulmonary disease (COPD) patients. " 01/01/2019 - "AZD8999 shows ~ 50% maximum inhibitory effect and similar potency inhibiting the released cytokines in neutrophils from healthy and COPD patients. " 01/01/2019 - "In summary, AZD8999 shows anti-inflammatory effects in neutrophils from COPD patients and induces synergistic anti-inflammatory effects when combined with fluticasone propionate, supporting the use of MABA/ICS combination therapy in COPD." 01/01/2019 - "Peripheral blood neutrophils from healthy and COPD patients were incubated with AZD8999 and fluticasone propionate, individually or in combination, for 1h followed by lipopolysaccharide (LPS) stimulation for 6h. " 01/01/2019 - "In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients."
2.	Respiratory Tract Diseases (Respiratory Tract Disease) 10/01/2017 - "LAS190792 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic respiratory diseases. " 01/01/2019 - "Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic respiratory diseases, induces potent and sustained relaxant effects in human bronchi by adressing both muscarinic acetylcholine receptors and β2-adrenoceptor. "

Related Drugs and Biologics

1.	Fluticasone (Cutivate)
2.	LAS190792
3.	Muscarinic Antagonists
4.	Cytokines
5.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
6.	Adrenergic Receptors (Adrenergic Receptor)
7.	Lipopolysaccharides

Related Therapies and Procedures

1.	Therapeutics